Rheumatology

Registration for the 7th IFPA Conference 2024 now open

Retrieved on: 
Tuesday, November 7, 2023
Knowledge, Psoriasis, Dermatology, Conference, Research, Antimicrobial spectrum, Patient, Rheumatology, Pharmaceutical industry, Nursing

STOCKHOLM, Nov. 7, 2023 /PRNewswire/ -- IFPA (International Federation of Psoriasis Associations) is thrilled to announce the 7th IFPA Conference (former World Psoriasis & Psoriatic Arthritis Conference), set to take place from June 27 to 29, 2024, in the vibrant city of Stockholm, Sweden.

Key Points: 
  • STOCKHOLM, Nov. 7, 2023 /PRNewswire/ -- IFPA (International Federation of Psoriasis Associations) is thrilled to announce the 7th IFPA Conference (former World Psoriasis & Psoriatic Arthritis Conference), set to take place from June 27 to 29, 2024, in the vibrant city of Stockholm, Sweden.
  • This year's conference theme, "Uncovering the Broad Spectrum of Psoriatic Disease," reflects the mission of IFPA to increase global recognition of the seriousness of psoriatic disease.
  • The IFPA Conference is a unique platform where delegates can explore psoriatic disease from various perspectives by networking with patients and industry representatives in attendance.
  • At the upcoming IFPA conference in Stockholm, we will share our knowledge and have meaningful conversations about these advances".

Registration for the 7th IFPA Conference 2024 now open

Retrieved on: 
Tuesday, November 7, 2023
Knowledge, Psoriasis, Dermatology, Conference, Research, Antimicrobial spectrum, Patient, Rheumatology, Pharmaceutical industry, Nursing

STOCKHOLM, Nov. 7, 2023 /PRNewswire/ -- IFPA (International Federation of Psoriasis Associations) is thrilled to announce the 7th IFPA Conference (former World Psoriasis & Psoriatic Arthritis Conference), set to take place from June 27 to 29, 2024, in the vibrant city of Stockholm, Sweden.

Key Points: 
  • STOCKHOLM, Nov. 7, 2023 /PRNewswire/ -- IFPA (International Federation of Psoriasis Associations) is thrilled to announce the 7th IFPA Conference (former World Psoriasis & Psoriatic Arthritis Conference), set to take place from June 27 to 29, 2024, in the vibrant city of Stockholm, Sweden.
  • This year's conference theme, "Uncovering the Broad Spectrum of Psoriatic Disease," reflects the mission of IFPA to increase global recognition of the seriousness of psoriatic disease.
  • The IFPA Conference is a unique platform where delegates can explore psoriatic disease from various perspectives by networking with patients and industry representatives in attendance.
  • At the upcoming IFPA conference in Stockholm, we will share our knowledge and have meaningful conversations about these advances".

Cabaletta Bio Receives FDA Clearance of CABA-201 IND Application for Treatment of Generalized Myasthenia Gravis

Retrieved on: 
Monday, November 6, 2023
GMG, Steroid, FDA, IND, Respiratory failure, Food, Enzyme inhibitor, Myositis, MG, Lupus, Autoantibody, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Protein, Disease, Clinical trial, Acetylcholine receptor, Risk, Neurology, Neuromuscular junction, Autoimmune disease, Scleroderma, NMJ, Patient, Investigational New Drug, Rheumatology, Fatigue, Pharmaceutical industry

PHILADELPHIA, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that the Company’s fourth Investigational New Drug (IND) application for CABA-201, a 4-1BB-containing fully human CD19-CAR T cell investigational therapy, has been allowed to proceed by the U.S. Food and Drug Administration (FDA) for a Phase 1/2 study in patients with generalized myasthenia gravis (gMG). The Company plans to initiate a Phase 1/2 clinical trial of CABA-201 across two parallel gMG cohorts based on autoantibody status – one cohort of six patients with acetylcholine receptor (AChR) antibody-positive gMG and a second cohort of six patients with AChR antibody-negative gMG. Consistent with the previously announced CABA-201 IND application clearances for lupus, myositis and systemic sclerosis, the starting dose for the Phase 1/2 trial evaluating CABA-201 in gMG will be 1 x 106 cells/kg.

Key Points: 
  • Consistent with the previously announced CABA-201 IND application clearances for lupus, myositis and systemic sclerosis, the starting dose for the Phase 1/2 trial evaluating CABA-201 in gMG will be 1 x 106 cells/kg.
  • The announcement of our fourth CABA-201 IND clearance is also our first IND clearance for the product candidate in a predominantly autoantibody mediated disease.
  • Generalized MG affects approximately 85% of the between 50,000 and 80,000 estimated MG patients in the United States.
  • Standard of care therapies include cholinesterase inhibitors, steroids, immunomodulators, and biologics, which often provide modest clinical effect and require chronic administration, increasing the risk of serious long-term side effects.

Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to T Cell-Mediated Inflammatory and Immune Diseases

Retrieved on: 
Wednesday, November 1, 2023
T helper 17 cell, Psoriasis, Medical research, Pulmonary fibrosis, Publication, Scleroderma, Preprint, Immunodeficiency, TGF, RNA, Cytokine, Fibrosis, GVHD, Research, Inflammation, INSERM, ITK, Induction, MMP2, Hôpital Cochin, Systemic, Clinical trial, Asthma, Atopic dermatitis, Cancer, IL-5, Memorial Sloan Kettering Cancer Center, Lymphoma, Chronic obstructive pulmonary disease, COPD, Enteropathy-associated T-cell lymphoma, Lupus, Extractive metallurgy, Vaccine, Rheumatology, Corvus, T helper cell

BURLINGAME, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the publication of preclinical data that demonstrated the potential of ITK inhibition as a novel approach to treat T cell-mediated inflammatory and immune diseases. Corvus’ ITK inhibitors include soquelitinib (formerly known as CPI-818), which was used in the preclinical studies and is currently in clinical trials for oncology indications, and several next-generation molecules that are being optimized for use in a variety of inflammatory and immune disease indications.

Key Points: 
  • “Our research on soquelitinib and selective ITK inhibition is uncovering valuable new information about immune function and the role of ITK in different diseases,” said James Rosenbaum, M.D., senior vice president of research at Corvus.
  • “The activity of soquelitinib in various inflammatory and immune disease models highlights the essential role of ITK in multiple T cell functions.
  • The publication is now available online as a preprint at bioRxiv.org and on the Publications and Presentations page of the Corvus website.
  • With this new publication, we further demonstrate the wide range of opportunities for ITK inhibition across specific indications with ongoing patient needs for new therapies.

Foundation for Sarcoidosis Research Announces 3 New Members to the 40 Member FSR Global Sarcoidosis Clinic Alliance through its FSR-GSCA Capacity Building Grants

Retrieved on: 
Wednesday, November 1, 2023
Rheumatology, Science, Research, Sarcoidosis, Education, Health, Washington University in St. Louis, Family, Rational ignorance, Critical care, New Jersey Medical School, Critical Care Medicine (journal), FSR, Division, Clinical trial, Hospital, Overalls, Patient, Health system, Associate, Pharmaceutical industry, Nursing, Rutgers University

FSR is dedicated to advancing the needs of all patients impacted with sarcoidosis and to closing the health care disparities gap that affects our community.

Key Points: 
  • FSR is dedicated to advancing the needs of all patients impacted with sarcoidosis and to closing the health care disparities gap that affects our community.
  • These capacity building grant recipients completed a competitive application process and have been awarded a complimentary 1-year membership (valued at $5,000) in the FSR-GSCA.
  • “Washington University is honored to become a member of the FSR Global Sarcoidosis Clinical Alliance.
  • "FSR is honored to have these three prestigious institutions join our extraordinary group of FSR Global Sarcoidosis Clinic Alliance members.

Medeor Therapeutics Announces Interim Data from Pivotal Trial Showing Cell Therapy Technology Could Eliminate Life-Long Need for Immunosuppressant Drugs Following Kidney Transplant

Retrieved on: 
Thursday, November 2, 2023
Biotechnology, Surgery, Health, Pharmaceutical, Clinical Trials, Survival, FDA, Standard of care, Regenerative Medicine Advanced Therapy, IND, Number needed to treat, Kidney disease, Stanford University, Immune tolerance, United Network for Organ Sharing, Diabetes, CTA, Infection, Kidney, Mental health, Cell, Jan Vansina, Society, Control, American Society of Nephrology, Quality of life, Clinical trial, ASN, Risk, Annual general meeting, Overmyer Network, Blood, University, Depression, Cancer, Anxiety, Therapy, SPA, Patient, Death, Immunosuppression, Transplant, Rheumatology, Protein toxicity, Pharmaceutical industry, Dentistry, Medical device, EU

Kidney transplant recipients who received a living donor kidney from an HLA-matched relative achieved functional tolerance and were free from the regimen of immunosuppressive drugs.

Key Points: 
  • Kidney transplant recipients who received a living donor kidney from an HLA-matched relative achieved functional tolerance and were free from the regimen of immunosuppressive drugs.
  • Typically, these drugs are required to prevent rejection and failure of the kidney transplant.
  • Study results will be presented during a late-breaking oral presentation at the American Society of Nephrology (ASN) Kidney Week 2023 Annual Meeting.
  • Following a kidney transplant, patients today are required to take daily immunosuppression medications for the rest of their lives to prevent rejection of the transplanted kidney.

Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2023 Financial and Operational Results

Retrieved on: 
Thursday, November 2, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Other Health, SLE, PSF, FDA, Insurance, American College, EGFR, U.S.–Canada Team Tournament (Go), Conversation, SG, EDGAR, SEDAR, American Society of Nephrology, AURORA, Nephrology, Lupus, Persistent environment, EC, Glomerular filtration rate, R, Society, Arthritis & Rheumatology, Bank statement, Growth, Risk, Marketing, Webcast, Analysis, Healthcare Improvement Scotland, American College of Rheumatology, Safety, LN, Investment, Management, Patient, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Rheumatology, Cryptocurrency, Pharmaceutical industry, Rare-earth element, Aurinia

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for the three and nine months ended September 30, 2023.

Key Points: 
  • Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for the three and nine months ended September 30, 2023.
  • Total net revenue was $54.5 million for the three months ended September 30, 2023 and $55.8 million for the same period in 2022.
  • Financial Results for the Three and Nine Months Ended September 30, 2023
    Total net revenue was $54.5 million and $55.8 million for the three months ended September 30, 2023 and September 30, 2022, respectively.
  • Aurinia will host a conference call and webcast to discuss the quarter ended September 30, 2023 financial results today, Thursday, November 2, 2023 at 8:30 a.m.

Alira Health and FORWARD Launch Enhanced Lupus Patient Registry, Accelerating Solutions for Patients

Retrieved on: 
Monday, November 6, 2023
Patient, Cohort (statistics), Data analysis, Rheumatology, Health, Rheumatism, Doctor of Philosophy, Comprehension, App Store (iOS/iPadOS), Research, Caregiver, Disease, Partnership, Hygiene, Electronic health record, Nursing, Pharmaceutical industry, Lupus

FRAMINGHAM, Mass., Nov. 6, 2023 /PRNewswire/ -- Alira Health, a global advisory and clinical research firm, and FORWARD, the National Databank for Rheumatic Diseases and largest patient-reported research databank for rheumatic disorders in the United States, announced today the launch of the enhanced Lupus Registry, enabling patients, caregivers, and research sponsors to gain better insights, and achieve better patient outcomes.

Key Points: 
  • FORWARD has established a collaborative partnership with Alira Health for administration and expansion of the registry, along with data analysis and reporting.
  • Alira Health will introduce innovative, streamlined data submission methods for patients via a mobile application known as Health Storylines™.
  • As part of the partnership, these individuals will all be invited to participate in the enhanced Lupus Registry on Health Storylines.
  • The data is managed and maintained by Alira Health in partnership with FORWARD to ensure data accuracy, hygiene, and quality.

Alira Health and FORWARD Launch Enhanced Lupus Patient Registry, Accelerating Solutions for Patients

Retrieved on: 
Monday, November 6, 2023
Patient, Cohort (statistics), Data analysis, Rheumatology, Health, Rheumatism, Doctor of Philosophy, Comprehension, App Store (iOS/iPadOS), Research, Caregiver, Disease, Partnership, Hygiene, Electronic health record, Nursing, Pharmaceutical industry, Lupus

FRAMINGHAM, Mass., Nov. 6, 2023 /PRNewswire/ -- Alira Health, a global advisory and clinical research firm, and FORWARD, the National Databank for Rheumatic Diseases and largest patient-reported research databank for rheumatic disorders in the United States, announced today the launch of the enhanced Lupus Registry, enabling patients, caregivers, and research sponsors to gain better insights, and achieve better patient outcomes.

Key Points: 
  • FORWARD has established a collaborative partnership with Alira Health for administration and expansion of the registry, along with data analysis and reporting.
  • Alira Health will introduce innovative, streamlined data submission methods for patients via a mobile application known as Health Storylines™.
  • As part of the partnership, these individuals will all be invited to participate in the enhanced Lupus Registry on Health Storylines.
  • The data is managed and maintained by Alira Health in partnership with FORWARD to ensure data accuracy, hygiene, and quality.

Alpine Immune Sciences to Present New Translational Data on Povetacicept and Acazicolcept in Systemic Lupus Erythematosus at American College of Rheumatology Convergence 2023

Retrieved on: 
Monday, October 30, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Rheumatology, BAFF, Inflammation, ALPN, Autoimmunity, American College, Pharmaceutical industry, Vaccine

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced the Company will present new translational data for povetacicept and acazicolcept in systemic lupus erythematosus at American College of Rheumatology Convergence 2023, November 10-15, 2023.

Key Points: 
  • Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced the Company will present new translational data for povetacicept and acazicolcept in systemic lupus erythematosus at American College of Rheumatology Convergence 2023, November 10-15, 2023.
  • Poster Title: Upregulation of Both APRIL and BAFF in Systemic Lupus Erythematosus Suggests Non-Redundant Roles, Further Revealed by Dual Inhibition with Povetacicept (ALPN-303)